Minimal disease activity (MDA) was more likely in people with psoriatic arthritis (PsA) when they initiated a disease-modifying anti-rheumatic drug (DMARD) earlier rather than later. That's according ...

Ageism in healthcare not only is frustrating and demoralizing for older patients but also negatively affects care. In rheumatology, patients with rheumatoid arthritis (RA) diagnosed later in life are ...

Please provide your email address to receive an email when new articles are posted on . Demographic factors were significantly associated with slower or faster initiation of b/ts DMARDs for RA.

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...

Please provide your email address to receive an email when new articles are posted on . Sustained DMARD-free remission “does not seem attainable” for patients with RA requiring biological DMARDs, but ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.